Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease

Russell W. Read, Fei Yu, Massimo Accorinti, Bahram Bodaghi, Soon Phaik Chee, Christine Fardeau, Hiroshi Goto, Gary N. Holland, Hidetoshi Kawashima, Eri Kojima, Phuc LeHoang, Claire Lemaitre, Annabelle A. Okada, Paola Pivetti-Pezzi, Antonio Secchi, Robert F. See, Khalid F. Tabbara, Masahiko Usui, Narsing A. Rao

Research output: Contribution to journalArticle

Abstract

Purpose: To compare the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Design: Retrospective comparative interventional case series. Methods: settings: Nine international uveitis specialty clinics. study population: Forty-eight patients presenting over a three-year period to a study center with acute Vogt-Koyanagi-Harada disease. intervention: Initial treatment with corticosteroid either orally (Oral only group) or intravenously followed by an oral taper (IV+Oral group). main outcome measures: Change in visual acuity with treatment; development of ocular complications, including visually significant cataract, choroidal neovascularization, subretinal fibrosis, fundus pigment migration, nummular hypopigmented lesions, and diffuse fundus depigmentation; use of immunosuppressive therapy. Results: The Oral only group comprised 15 patients (31%) and the IV+Oral group 33 patients (69%). Median follow-up was 15 months. There was no difference in duration of follow-up between groups (P = .234). There was no difference in the change in visual acuity between groups, adjusting for initial visual acuity (P = .402). There were no differences in the rates of development of visually significant cataract, fundus pigmentary changes, or in the rate of use of subsequent immunosuppressive therapy between treatment groups. No patients developed choroidal neovascularization or subretinal fibrosis over the study period. Conclusions: Route of administration of corticosteroid had no detectable effect on change in visual acuity nor on the development of visually significant complications over the study period. Prospective trials are necessary to address speed of resolution and definitively answer outcome questions.

Original languageEnglish (US)
Pages (from-to)119-124
Number of pages6
JournalAmerican Journal of Ophthalmology
Volume142
Issue number1
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Uveomeningoencephalitic Syndrome
Adrenal Cortex Hormones
Visual Acuity
Choroidal Neovascularization
Immunosuppressive Agents
Cataract
Fibrosis
Therapeutics
Uveitis
Outcome Assessment (Health Care)
Population

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease. / Read, Russell W.; Yu, Fei; Accorinti, Massimo; Bodaghi, Bahram; Chee, Soon Phaik; Fardeau, Christine; Goto, Hiroshi; Holland, Gary N.; Kawashima, Hidetoshi; Kojima, Eri; LeHoang, Phuc; Lemaitre, Claire; Okada, Annabelle A.; Pivetti-Pezzi, Paola; Secchi, Antonio; See, Robert F.; Tabbara, Khalid F.; Usui, Masahiko; Rao, Narsing A.

In: American Journal of Ophthalmology, Vol. 142, No. 1, 07.2006, p. 119-124.

Research output: Contribution to journalArticle

Read, RW, Yu, F, Accorinti, M, Bodaghi, B, Chee, SP, Fardeau, C, Goto, H, Holland, GN, Kawashima, H, Kojima, E, LeHoang, P, Lemaitre, C, Okada, AA, Pivetti-Pezzi, P, Secchi, A, See, RF, Tabbara, KF, Usui, M & Rao, NA 2006, 'Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease', American Journal of Ophthalmology, vol. 142, no. 1, pp. 119-124. https://doi.org/10.1016/j.ajo.2006.02.049
Read, Russell W. ; Yu, Fei ; Accorinti, Massimo ; Bodaghi, Bahram ; Chee, Soon Phaik ; Fardeau, Christine ; Goto, Hiroshi ; Holland, Gary N. ; Kawashima, Hidetoshi ; Kojima, Eri ; LeHoang, Phuc ; Lemaitre, Claire ; Okada, Annabelle A. ; Pivetti-Pezzi, Paola ; Secchi, Antonio ; See, Robert F. ; Tabbara, Khalid F. ; Usui, Masahiko ; Rao, Narsing A. / Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease. In: American Journal of Ophthalmology. 2006 ; Vol. 142, No. 1. pp. 119-124.
@article{80980ea9fd224d51add212c07533dfbe,
title = "Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease",
abstract = "Purpose: To compare the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Design: Retrospective comparative interventional case series. Methods: settings: Nine international uveitis specialty clinics. study population: Forty-eight patients presenting over a three-year period to a study center with acute Vogt-Koyanagi-Harada disease. intervention: Initial treatment with corticosteroid either orally (Oral only group) or intravenously followed by an oral taper (IV+Oral group). main outcome measures: Change in visual acuity with treatment; development of ocular complications, including visually significant cataract, choroidal neovascularization, subretinal fibrosis, fundus pigment migration, nummular hypopigmented lesions, and diffuse fundus depigmentation; use of immunosuppressive therapy. Results: The Oral only group comprised 15 patients (31{\%}) and the IV+Oral group 33 patients (69{\%}). Median follow-up was 15 months. There was no difference in duration of follow-up between groups (P = .234). There was no difference in the change in visual acuity between groups, adjusting for initial visual acuity (P = .402). There were no differences in the rates of development of visually significant cataract, fundus pigmentary changes, or in the rate of use of subsequent immunosuppressive therapy between treatment groups. No patients developed choroidal neovascularization or subretinal fibrosis over the study period. Conclusions: Route of administration of corticosteroid had no detectable effect on change in visual acuity nor on the development of visually significant complications over the study period. Prospective trials are necessary to address speed of resolution and definitively answer outcome questions.",
author = "Read, {Russell W.} and Fei Yu and Massimo Accorinti and Bahram Bodaghi and Chee, {Soon Phaik} and Christine Fardeau and Hiroshi Goto and Holland, {Gary N.} and Hidetoshi Kawashima and Eri Kojima and Phuc LeHoang and Claire Lemaitre and Okada, {Annabelle A.} and Paola Pivetti-Pezzi and Antonio Secchi and See, {Robert F.} and Tabbara, {Khalid F.} and Masahiko Usui and Rao, {Narsing A.}",
year = "2006",
month = "7",
doi = "10.1016/j.ajo.2006.02.049",
language = "English (US)",
volume = "142",
pages = "119--124",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease

AU - Read, Russell W.

AU - Yu, Fei

AU - Accorinti, Massimo

AU - Bodaghi, Bahram

AU - Chee, Soon Phaik

AU - Fardeau, Christine

AU - Goto, Hiroshi

AU - Holland, Gary N.

AU - Kawashima, Hidetoshi

AU - Kojima, Eri

AU - LeHoang, Phuc

AU - Lemaitre, Claire

AU - Okada, Annabelle A.

AU - Pivetti-Pezzi, Paola

AU - Secchi, Antonio

AU - See, Robert F.

AU - Tabbara, Khalid F.

AU - Usui, Masahiko

AU - Rao, Narsing A.

PY - 2006/7

Y1 - 2006/7

N2 - Purpose: To compare the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Design: Retrospective comparative interventional case series. Methods: settings: Nine international uveitis specialty clinics. study population: Forty-eight patients presenting over a three-year period to a study center with acute Vogt-Koyanagi-Harada disease. intervention: Initial treatment with corticosteroid either orally (Oral only group) or intravenously followed by an oral taper (IV+Oral group). main outcome measures: Change in visual acuity with treatment; development of ocular complications, including visually significant cataract, choroidal neovascularization, subretinal fibrosis, fundus pigment migration, nummular hypopigmented lesions, and diffuse fundus depigmentation; use of immunosuppressive therapy. Results: The Oral only group comprised 15 patients (31%) and the IV+Oral group 33 patients (69%). Median follow-up was 15 months. There was no difference in duration of follow-up between groups (P = .234). There was no difference in the change in visual acuity between groups, adjusting for initial visual acuity (P = .402). There were no differences in the rates of development of visually significant cataract, fundus pigmentary changes, or in the rate of use of subsequent immunosuppressive therapy between treatment groups. No patients developed choroidal neovascularization or subretinal fibrosis over the study period. Conclusions: Route of administration of corticosteroid had no detectable effect on change in visual acuity nor on the development of visually significant complications over the study period. Prospective trials are necessary to address speed of resolution and definitively answer outcome questions.

AB - Purpose: To compare the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Design: Retrospective comparative interventional case series. Methods: settings: Nine international uveitis specialty clinics. study population: Forty-eight patients presenting over a three-year period to a study center with acute Vogt-Koyanagi-Harada disease. intervention: Initial treatment with corticosteroid either orally (Oral only group) or intravenously followed by an oral taper (IV+Oral group). main outcome measures: Change in visual acuity with treatment; development of ocular complications, including visually significant cataract, choroidal neovascularization, subretinal fibrosis, fundus pigment migration, nummular hypopigmented lesions, and diffuse fundus depigmentation; use of immunosuppressive therapy. Results: The Oral only group comprised 15 patients (31%) and the IV+Oral group 33 patients (69%). Median follow-up was 15 months. There was no difference in duration of follow-up between groups (P = .234). There was no difference in the change in visual acuity between groups, adjusting for initial visual acuity (P = .402). There were no differences in the rates of development of visually significant cataract, fundus pigmentary changes, or in the rate of use of subsequent immunosuppressive therapy between treatment groups. No patients developed choroidal neovascularization or subretinal fibrosis over the study period. Conclusions: Route of administration of corticosteroid had no detectable effect on change in visual acuity nor on the development of visually significant complications over the study period. Prospective trials are necessary to address speed of resolution and definitively answer outcome questions.

UR - http://www.scopus.com/inward/record.url?scp=33745640944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745640944&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2006.02.049

DO - 10.1016/j.ajo.2006.02.049

M3 - Article

C2 - 16815259

AN - SCOPUS:33745640944

VL - 142

SP - 119

EP - 124

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -